[Fluctuation of C-reactive protein levels in acute coronary syndrome].
The aim of the study was to find out whether early use of atorvastatin in patients with acute coronary syndrome is associated with rapid changes of plasma levels of the marker of inflammation -- C-reactive protein. 32 patients (15 male, 17 female; no more then 3 hours from pain onset, age 61+/-10 years) treated with AHA recommendations, were assigned to the two groups. In the I group (n=17) patients received atorvastatin (liprimar) 40 mg/day, II group (n=15) represented the control group. Plasma level of C-reactive protein (hs-CRP) was assessed by highly sensitive method at baseline, on days 7 and 14. Baseline clinical characteristics and C-reactive protein level were similar in all groups. C-reactive protein level was increased in both groups from the baseline on day 7 (p<0.01). In group I C-reactive protein level was decreased by 16.54% from the baseline on day 14 (from 22.48+/-1.65 to 18.76+/-1.55 mg/l, p=1.7). In II group C-reactive protein level was increased by 9.12% from baseline on day 14 (from 22.79+/-1.67 to 24.87+/-1.24 mg/l, p<0.0005). In patients with acute coronary syndrome early use of atorvastatin was associated with rapid decrease of C-reactive protein level.
Kadzhaia
G V
GV
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000924:Anticholesteremic Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D000069059:Atorvastatin; D002097:C-Reactive Protein / Q000378:metabolism*; D003324:Coronary Artery Disease / Q000097:blood* / Q000188:drug therapy*; D005260:Female; D006538:Heptanoic Acids / Q000494:pharmacology* / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011758:Pyrroles / Q000494:pharmacology* / Q000627:therapeutic use*
D000924:Anticholesteremic Agents; D006538:Heptanoic Acids; D011758:Pyrroles; D002097:C-Reactive Protein; D000069059:Atorvastatin